On July 22, Gelunhui | BMO Capital raised AbbVie's target price from $180 to $214, maintaining an 'outperform' rating on large cap.
BMO Capital上调艾伯维目标价至214美元
BMO Capital raised AbbVie's target price to $214.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.